Abstract：OBJECTIVE: To study the impact of gonadotropinreleasing hormone analogs (GnRHa) on body mass index (BMI) in girls with idiopathic central precocious puberty (ICPP). METHODS: One hundred and thirty-four girls with ICPP were enrolled. Fifty-seven out of the 134 girls were treated with GnRHa for 1.69±0.43 years. The height, weight, bone age and BMI were measured before treatment, at the end of the treatment and after reaching near adult height and compared with those in the untreated 77 girls. RESULTS: The adult predicted height standard deviation score (SDS) at the end of treatment was significantly higher than that before treatment (P0.05). With GnRHa treatment, the near-adult height SDS was higher than the target height SDS (P0.05). A significant reduction in the BMI was observed when reaching the near-adult height in the GnRHa treatment group compared to the level of pretreatment and the untreated group (P<0.01). However, the BMI in the GnRHa treatment group before treatment, at the end of the treatment and after reaching near adult height remained in the normal range (±1 SD). CONCLUSIONS: GnRHa may improve the final height in girls with ICPP. The alterations of BMI after GnRHa therapy fluctuate in a normal range.
YUAN Jin-Na,LIANG Li,CAI Xi-Ding et al. Impact of gonadotropin-releasing hormone analogs on body mass index in girls with idiopathic central precocious puberty: a long-term follow-up study[J]. CJCP, 2011, 13(11): 896-899.
［1］Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropinreleasing hormone analogs in children［J］. Pediatrics, 2009, 123(4): e752-e762.
［2］Chiocca E, Dati E, Baroncelli GI, Mora S, Parrini D, Erba P, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty data at near final height［J］. Neuroendocrinology, 2009, 89(4): 441-447.
［3］Paterson WF, McNeill E, Young D, Donaldson MDC. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty［J］. Clin Endocrinol (Oxf), 2004, 61(5): 626-634.
［7］Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function［J］. J Clin Endocrinol Metab, 2008, 93(1): 190-195.
［9］Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, Lorini R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height［J］. Eur J Endocrinol, 2005, 152(3): 463-464.
［10］Kaplowitz PB, Slora EJ, Wasserman RC, Pedlow SE, Herman-Giddens ME. Earlier onset of puberty in girls: relation to increased body mass index and race［J］. Pediatrics, 2001, 108(2): 347-353.
［11］Wang Y. Is obesity associated with early sexual maturation? A comparison of the association in American boys versus girls［J］. Pediatrics, 2002, 110(5): 903-910.
［12］Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment［J］. Gynecol Endocrinol, 2011, 27(8): 524-528.
［13］Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men［J］. Asian J Androl, 2008, 10(4):525-534.
［14］Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity［J］. J Clin Endocrinol Metab, 2007, 92(9): 3483-3489.
